PDCD1 and cancer: ICIs block immune escape and induce active inflammation against cancer cells by targeting immune checkpoint proteins, such as programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), and have recently been used as a strikingly effective treatment for several types of cancers.